Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal refl...
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatm...
Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor str...
Phathom Pharmaceuticals (NASDAQ:PHAT) sees FY2025 sales of $165.000 million-$175.000 million vs $159.818 million analyst estimate.
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate ...
